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Research Article 
ABSTRACT  The various symptomatic outcomes of cutaneous leishmaniasis 
relates to the type and potency of its underlying inflammatory responses. 
Presence of the cytoplasmic Leishmania RNA virus-1 (LRV1) within Leishmania 
guyanensis, worsens lesional inflammation and parasite burden, as the viral 
dsRNA genome acts as a potent innate immunogen stimulating Toll-Like-
Receptor-3 (TLR3). Here we investigated other innate pattern recognition re-
ceptors capable of reacting to dsRNA and potentially contributing to LRV1-
mediated inflammatory pathology. We included the cytoplasmic dsRNA sen-
sors, namely, the RIG-like receptors (RLRs) and the inflammasome-dependent 
and -independent Nod-like-receptors (NLRs). Our study found no role for RLRs 
or inflammasome-dependent NLRs in the pathology of L. guyanensis infection 
irrespective of its LRV1-status. Further, neither LRV1-bearing L. guyanensis 
(LgyLRV1+) nor LRV1-negative L. guyanensis (LgyLRV1-) activated the inflam-
masome in vitro. Interestingly, similarly to L. donovani, L. guyanensis infec-
tion induced the up-regulation of the A20 protein, known to be involved in 
the evasion of inflammasome activation. Moreover, we observed that 
LgyLRV1+ promoted the transcription of inflammasome-independent NLRC2 
(also called NOD2) and NLRC5. However, only NLRC2 showed some contribu-
tion to LRV1-dependent pathology. These data confirmed that the endosomal 
TLR3 pathway is the dominant route of LRV1-dependent signalling, thus ex-
cluding the cytosolic and inflammasome pathways. We postulate that avoid-
ance of the inflammasome pathways is likely an important mechanism of 
virulence in Leishmania infection irrespective of the LRV1-status. 
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INTRODUCTION 
The human protozoan parasite Leishmania is highly immu-
no-stimulatory, presenting to the host cell a variety of po-
tent pathogen-associated molecular patterns (PAMPs) that 
shape the outcome of the inflammatory skin disease 
known as cutaneous leishmaniasis (CL) [1]. CL is a prevalent 
but neglected tropical disease affecting over 2 million peo-
ple per year with an expanding geographical reach and a 
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diverse clinical presentation. The various symptomatic out-
comes of CL can be categorised by the type and potency of 
its underlying inflammatory response: ranging from a sin-
gle, self-healing lesion at the site of inoculation to chronic 
hyper-inflammatory tissue destruction and the establish-
ment of disfiguring metastatic lesions that are refractory to 
routine therapies [2]. These inflammatory responses have 
a high-degree of species-specificity, where metastatic and 
chronic complications occur mainly in infections of the 
Leishmania Viannia subgenus found in Central and South 
America [3] [4]. 
We previously identified a cytoplasmic dsRNA virus 
within metastatic L. guyanensis (Lgy) parasites that acts as 
a potent innate immunogen capable of worsening lesional 
inflammation [5] and prolonging infected macrophage sur-
vival [6]. The dsRNA genome of Leishmania RNA virus 
(LRV1) binds to and stimulates endosomal Toll-Like-
Receptor-3 (TLR3), inducing destructive hyper-
inflammation [5] and metastasis in an immunosuppressed 
environment [7]. Further, the presence of LRV1 in L. guya-
nensis and L. braziliensis negatively affects the patients 
response to anti-Leishmania drugs, as it is predictive of 
treatment failure and symptomatic relapses [8, 9], and 
potentially worsens the disease outcome in patients co-
infected with HIV [10]. 
By recognising PAMPs and danger-associated molecular 
patterns (DAMPs) via innate pattern recognition receptors 
(PRRs), the mammalian immune system can respond rapid-
ly to infection and tissue damage. These PRRs are able to 
initiate a wide variety of robust inflammatory pathways 
tailored to suit the stimulatory ligand. Depending on their 
ligand specificity, localization and signalling pathway, PRRs 
are classified into three major families: the TLRs (Toll-like 
receptors), the RLRs (retinoic acid-inducible gene-I-like 
receptors) [11] and the NLRs (nucleotide-binding-domain, 
leucine-rich repeat containing receptors). 
RLRs are a small family of RNA helicase enzymes found 
exclusively in the cytosol that launch an anti-viral response 
after binding cytosolic RNA [12]. Most active in dendritic 
cells (DCs), macrophages and fibroblasts, RLRs comprise of 
two major family members: RIG-I (retinoic acid-inducible 
gene-I) and MDA-5 (melanoma differentiation-associated 
protein 5) that are activated by binding cytosolic RNA. RIG-I 
typically recognizes 5’ triphosphate short uncapped dsRNA 
and ssRNA, while MDA-5 recognises longer dsRNA strands 
[13]. Both RIG-I and MDA-5 signal through a common 
adaptor molecule, MAVS (mitochondrial antiviral signalling 
protein) to induce a type I interferon (IFN) mediated antivi-
ral response via IRF-3 as well as an NF-B-type inflammato-
ry response [14]. As RLRs are present in the cytosol, their 
involvement in LRV1-mediated leishmaniasis would indi-
cate that LRV1 is able to exit the phagolysosome, where 
the parasite survives, and to reach the host cell cytoplasm. 
DAMPs such as intracellular content released from dy-
ing cells (e.g. nucleic acids, heat-shock proteins and ATP) or 
damaged components of the extracellular matrix (e.g. hya-
luronic acid) are recognised by NLRs. NLR sensing of 
DAMPs can result in a potent immune response or an in-
flammatory form of cell death, termed pyroptosis. Addi-
tionally, several NLRs are able to respond to PAMPs such as 
bacterial cell wall components and viral RNA. NLR activa-
tion can be accomplished in a fashion similar to that of 
TLRs, where NF-B or IRFs are mobilised to produce pro-
inflammatory cytokines or type I IFNs, respectively. Alter-
natively, several NLRs can oligomerise to form a large mac-
romolecular scaffold, called the “inflammasome”. Current-
ly, 7 of the 22 human NLR members are known to oligo-
merise into inflammasomes, namely, NRLB/NLRC4 [15] and 
NLRP-1, -3, -6, -7, and -12 [16-20]. The inflammasome re-
cruits and activates inflammatory caspases leading to the 
cleavage and activation of pro-IL-1β and pro-IL-18 [21, 22]. 
They are formed by the oligomerization of caspase activa-
tion and recruitment domains (CARDs), which are either 
included in the NLR structure such as NLRC4 and NLRP1 or 
recruited in an ASC (apoptosis-associated speck-like pro-
tein containing CARD) protein, which is the case for the 
formation of the NLRP3, 6, 7, and 12 inflammasome. Addi-
tionally, the non-NLR protein, absent in melanoma 2 
(AIM2), which contains pyrin and HIN200 domains, senses 
dsDNA to form an inflammasome by ASC recruitment [23]. 
To date, only a few studies have thoroughly explored 
the role of inflammasomes in leishmaniasis. The clearance 
of L. amazonensis, L. infantum and L. braziliensis species is 
correlated to an NLRP3-dependent production of nitric 
oxide and IFN-γ [24]. The authors show that the NLRP3 
inflammasome activates IL-1β, and that the IL-1 receptor 
and its MyD88 adaptor protein are necessary and sufficient 
to trigger parasitotoxic oxidative stress. Different compo-
nents of the NLRP3 inflammasome were found to be up-
regulated also in a macrophage system of L. major infec-
tion [25]. However, oppositely to the observation in L. in-
fantum and L. braziliensis, inflammasome activation wors-
ens the outcome of L. major infection, accelerating the 
course of disease or inducing non-healing lesions [26, 27]. 
Predictably, the effects of inflammasome activity could 
differ widely amongst various Leishmania species, ranging 
from protective in L. amazonensis, L. infantum and L. 
braziliensis infection [24] to pathogenic in cutaneous spe-
cies from the Paleotropics [26, 27] and contrasting in vis-
ceralizing L. donovani, where it has been involved in the 
development of protective immunity [28] but has also re-
cently been correlated with increased visceralization if 
activated by gut bacteria transmitted during a sand fly bite 
[29]. Of note, however, IL-1α, IL-1β and IL-18 can be acti-
vated independently of the inflammasome [30] and thus 
these roles are not necessarily indicative of NLR activity. 
Recently, A20 (also named TNF-α-induced protein 3), a 
deubiquitinating protein, was reported to inhibit NF-κB 
activation by deubiquitinating TRAF6 and also to block in-
flammasome activation by inhibiting IL-1β maturation in-
dependently of its effect on NF-kB [31]. In L. donovani in-
fection, A20 was shown to inhibit TLR signalling, decreasing 
the pro-inflammatory response, thus favouring parasite 
survival [32] by blocking both pro-IL-1β and pro-caspase-1 
maturation [33].   
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In this study, we investigated the role of several non-
TLR3 pathways of viral dsRNA recognition during LRV1-
mediated pathology in a murine model of Lgy infection. To 
this end, we performed an expression array of NLR and RLR 
components in Lgy infection, probing for markers of Lgy 
induced inflammasome activation at a cellular level. We 
then tested the role of these components on LRV1-
dependent leishmanial pathology in a murine model of 
infection. 
 
RESULTS  
LRV1 does not activate RLR signaling 
MAVS is the common adaptor molecule essential in the 
signalling of RIG-I and MDA-5 [34]. Therefore, to investi-
gate whether RLRs contributed to LRV1-mediated parasite 
survival and inflammation, we infected bone marrow de-
rived macrophages (BMDMs) from C57BL/6 (WT) and 
MAVS-/- mice with LgyLRV1+ or LgyLRV1- parasites. We 
found that the absence of MAVS did not affect LRV1-
induced up-regulation of the signature NF-B cytokines IL-
6 and TNF-α (Fig 1A and 1B). Subsequently, to include the 
effect of all cells in which RLRs may be activated in the 
context of the leishmanial lesion, we monitored disease 
progression in a murine model of infection. Here, mice 
lacking MAVS signalling did not show any visible variation 
in lesional swelling (Fig 1C) or parasite burden (Fig 1D), as 
compared to the WT control. Thus, we could exclude RLRs 
as sensor molecules participating in an LRV1-dependent 
exacerbation of the disease and conclude that LRV1 dsRNA 
does not reach the host cell cytoplasm. 
FIGURE 1: LRV1 does not activate RLR signaling. (A, B) BMDMs from mice deficient in MAVS and their C57BL/6 WT counterparts were in-
fected with LgyLRV1+ or LgyLRV1- parasites or stimulated with a synthetic TLR3 ligand, poly(I:C). After 24 hours, the NF-B cytokines, IL-6 
(A) and TNF-α (B) in BMDM supernatant were quantified by ELISA. (C, D) MAVS-/- and C57BL/6 WT mice were infected with LgyLRV1+ or 
LgyLRV1- parasites in their hind footpads. (C) Weekly lesional swelling was monitored as a proxy for disease progression. (D) At the peak of 
infection (4 weeks), parasite burden was measured by in vivo luminescence, by injecting mice intra-peritoneally with 15 mg/kg luciferin. 
Data is representative of a minimum of three independent experiments, using at least five mice per condition, and showed as mean ± SEM. 
Significance tested by Student’s t-test (bar graphs) or one-way Anova (disease score), ns: non-significant. 
M.-A. Hartley et al. (2018)  Leishmania guyanensis evades the inflammasome 
 
 
OPEN ACCESS | www.microbialcell.com 4 Microbial Cell | in press 
LRV1 promotes the transcription of the inflammasome 
components, caspase-1, IL-1β, NLRP3 and AIM2 
To identify the possible interaction between LRV1 and the 
inflammasome, we performed an expression assay of the 
key inflammasome signalling transducers as well as the 
major inflammasome-forming PRR family. We focused on 
genes encoding the common inflammasome components 
asc, caspase 1 and il1beta (Fig 2A), and the inflammasome-
forming members nlrc4 and naip5 (Fig 2B), the NLRP family 
members nlrp1, nlrp3, nlrp12 (Fig 2C) and a non-NLR in-
flammasome-forming molecule aim2 (Fig 2D). BMDMs 
were infected with LgyLRV1+ or LgyLRV1- parasites, or 
stimulated with the synthetic TLR3 agonist, poly(I:C), and 
then prepared for qRT-PCR analysis. We found that TLR3 
stimulation was able to potently induce the transcription of 
genes including caspase-1, IL-1β, nlrp3 and aim2 but not 
asc, nlrc4, naip5, nlrp1 and nlrp12 (Fig 2). Taken together, 
these results showed that LRV1 and poly(I:C) mediated 
TLR3 activation can prime the inflammasome components 
and promote the transcription of certain NLRs and AIM2. 
 
L. guyanensis does not activate the inflammasome in 
macrophages, irrespective of its LRV1 status 
Based on the transcriptional data, we could expect that 
LRV1 would activate the inflammasome. Such activation 
involves the autocatalytic cleavage of pro-caspase 1 into its 
p20 and p10 subunits. In turn, active caspase-1 cleaves and 
activates pro-IL-1β and pro-IL-18. Importantly, while pro-IL-
18 and pro-caspase-1 are constitutively expressed, the 
transcription of pro-IL-1β is under the control of NF-κB. 
Therefore, inflammasome activity requires a “priming” 
step via NF-κB activation before a second signal activates 
the inflammasome. NF-κB-dependent TLR3 signalling as 
observed in dsRNA activation is one such pathway leading 
to inflammasome priming [22, 35].  
To investigate whether we were able to activate the in-
flammasome in our BMDMs, we primed BMDMs with lipo-
polysaccharide (LPS) for 3 hours before LgyLRV1+ or 
LgyLRV1- infection, and added nigericin treatment as a 
positive control of inflammasome activation. Cell lysates 
and cell culture supernatants were probed for the pro- and 
cleaved forms of caspase-1 by immunoblotting (Fig 3A). 
LgyLRV1+ infection or poly(I:C) treatment increased the 
expression of the  pro-form of IL-1β,  and thus acted as  pri- 
FIGURE 2: LRV1 promotes the transcription of the inflammasome components, caspase-1, IL-1β, NLRP3 and AIM2. BMDMs from C57BL/6 
mice were infected with LgyLRV1+ or LgyLRV1- parasites or stimulated with a synthetic TLR3 ligand, poly(I:C). After 6 hours and 12 hours, 
mRNA was quantified by qRT-PCR. (A) The common inflammasome components ASC, Caspase-1 and IL-1β and the inflammasome-forming 
members of the (B) NLRC family, (C) NLRP family and (D) a non-NLR inflammasome-forming molecule, AIM2 were measured. Levels are 
representative of both 6-hour and 12-hour time points. Representative results are shown from at least three independent experiments, 
using two technical and two biological replicates, and showed as mean ± SEM. Non-parametric Student’s t-test is shown. *p < 0.05, **p < 
0.01, ***p < 0.001. A cut off value of 2-fold was used as a limit of significance and is indicated as a dotted line. 
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ming signals. However, L. guyanensis parasites, irrespective 
of their LRV1 status did not activate the inflammasome in 
BMDMs, since the IL-1β cytokine and cleaved active caspa-
se-1 could not be detected in the cell supernatant (Fig 3A 
and 3B). Taken together, we were able to definitively ex-
clude inflammasome activation in the macrophage host 
cell during infection with L. guyanensis parasites. 
 
The inflammasome does not contribute to disease pa-
thology in a murine model of Lgy infection, irrespective of 
its LRV1 status 
As the macrophage is just one of the many cells with po-
tential inflammasome activity in the skin [36, 37], it was 
important to verify inflammasome activity in the physiolog-
ical context of an in vivo infection. Using mice deficient in 
caspase1/11 (thus lacking both the canonical caspase-1-
dependent and non-canonical caspase-11-dependent 
pathway of inflammasome activation [38]) or ASC, we 
found no significant differences in the development of 
lesional swellings for Lgy infection, irrespective of LRV1 
presence (Fig 4A and 4B). These mice also did not display 
any differences in parasite burden at the peak of infection 
as quantified by in vivo luminescence (Fig 4C and 4D). 
Moreover, the conditional knockouts of a floxed asc gene 
using CRE expression in DCs, macrophages or keratinocytes 
mediated by promoters Itgax (CD11c), lysosome 2 (LysM) 
and keratin 14 (K14), respectively, did not affect the LRV-
mediated disease progression in mice, thus allowing us to 
exclude the contribution of the inflammasome of other cell 
types such as DCs, neutrophils and keratinocytes that are 
present in lesions (Fig S1). Consistent with these results, 
the parasite burden in macrophages deficient in ASC, 
caspase-1 and IL-1β were similar to WT macrophages 24 
hours post infection (Fig 4E). In conclusion, the inflam-
masome did not have any effect on lesional pathology or 
parasite burden in Lgy infection irrespective of its LRV1 
status. 
 
L. guyanensis induces the expression of the inflam-
masome-inhibitor protein A20 
Recently, A20 was further shown to promote L. donovani 
virulence, as it inhibits inflammasome formation possibly 
by blocking pro-IL-1β and procaspase-1 maturation [33]. 
Considering that we observed an inhibition of the activa-
tion of the inflammasome, we investigated whether 
LgyLRV1+ or LgyLRV1- could induce the expression of A20. 
We therefore infected BMDMs with LgyLRV1+ or LgyLRV1- 
and analysed cell lysates for increased expression of A20 by 
immunoblot at 4 and 8 hours post infection. As a positive 
control, we infected BMDMs with two strains of L. infan-
tum and analysed A20 expression. Similarly to L. infantum, 
in our model of macrophage infection, LgyLRV1+ and 
LgyLRV1- induced the expression of A20 (Fig 5A), suggest-
ing its possible involvement in the inhibition of inflam-
masome activation by blocking IL-1β maturation [31]. To 
better assess LRV1 involvement in A20 induction, we quan-
tified by densitometric analysis the expression of A20 in 
LgyLRV1+ or LgyLRV1- infected or poly(I:C) treated macro-
phages. Interestingly, at early time points, infection with 
LgyLRV1+ parasites significantly increased A20 expression 
compared to both LgyLRV1- infection or poly(I:C) treat-
ment, suggesting an additive effect between Leishmania 
infection and TLR3 stimulation (Fig 5B). 
 
 
FIGURE 3: L. guyanensis does not activate the inflammasome in macrophages, irrespective of its LRV1 status. (A-B) BMDMs from C57BL/6 
WT mice were primed with 200 ng/ml of LPS for 3 hours. Subsequently, cells were incubated with LgyLRV1+ or LgyLRV1- parasites, poly(I:C) 
or culture medium. Additionally, a 1 hour treatment with 5 µM of Nigericin was used as a positive control for the inflammasome activation. 
Proteins were extracted from cell lysates (CL) and supernatants (SN). (A) Cell lysates were blotted for caspase-1. (B) IL-1β detected by ELISA 
in cell-free supernatant. Graphs are representative of a minimum of three independent experiments, using four technical and two biological 
replicates, and showed as mean ± SEM. Non-parametric Student’s t-test was used to calculate significance. 
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LRV1 induces the expression of inflammasome-
independent NLRs: NLRC1, NLRC2 and NLRC5 
Many of the inflammasome-independent NLR family mem-
bers are able to recognise viral components and often use 
signalling pathways similar to that of the TLR3-LRV1 re-
sponse. To identify NLRs of interest in our model, we 
screened BMDMs for LRV1-induced expression of the in-
flammasome-independent NLR members that are known 
components of the anti-viral response.   
NLRC2 can act as a cytoplasmic PRR for ssRNA, the rep-
licative RNA and mRNA of Totiviridae [39], and signal 
through MAVS to promote IFN-β transcription via IRF3 [40]. 
However, in macrophages stimulated with poly(I:C) NLRC2 
is not implicated in the production of IFN-β, TNF-α and IL-6 
[40]. Oppositely, it was reported that NLRC1 and NLRC2 are 
induced in response to viral infection, poly(I:C) or IFN-β 
stimulation and to enhance the production of pro-
inflammatory cytokines [41]. Further, NLRC2 promotes the 
CCL2-dependent recruitment of inflammatory monocytes 
[42]. To test for the expression of NLRC1 and NLRC2 in our 
in vitro infection model, we infected WT BMDMs with 
LgyLRV1+ or LgyLRV1- parasites, or stimulate them with 
poly(I:C). Six hours post infection, BMDMs were lysed and 
the expression of different NLR transcript was measured by 
qRT-PCR. In accordance with published data, we observed 
that  both  LRV1  and  poly(I:C)   stimulation  promoted  the  
FIGUER 4: The inflammasome does not contribute to disease pathology in a murine model of Lgy infection, irrespective of its LRV1 sta-
tus. WT, ASC-/- and Caspase1/11-/- mice were infected with LgyLRV1+ or LgyLRV1- parasites in their hind footpads. (A, B) Weekly lesional 
swelling was monitored as a proxy for disease progression. (C, D) At the peak of infection (4 weeks), parasite burden was measured by in 
vivo luminescence, by injecting mice intra-peritoneally with 15mg/kg luciferin. (E) BMDMs derived from C57BL/6 mice deficient in ASC, 
Caspase-1/11 and IL-1β were infected with either LgyLRV1+ or LgyLRV1- parasites for 24 hours then stained with DAPI and acquired using 
high-content microscopy. Parasite burden was unbiasedly quantified using computational image analysis. The data shown is representative 
of a minimum of three independent experiments, using at least 5 mice per condition, and showed as mean ± SEM. Statistical significance 
was quantified by performing Student’s t-test (bar graphs) or one-way Anova (disease score), ns: non-significant. 
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transcription of nlrc1 and nlrc2 (Fig 6A). Further, it was 
reported that NLRX1 [43], NLRC3 [44] and NLRC5 [45, 46] 
negatively regulate mitochondrial antiviral immune signal-
ling. Here, we observed that the stimulation of macro-
phages with poly(I:C) or LgyLRV1+ resulted in the induction 
of nlrc5 (Fig 6B), whereas the expression of nlrx1 and nlrc3 
was unaltered (Fig 6B). Together, these results indicated 
that LRV1-mediated TLR3 activation can act as a priming 
signal for certain inflammasome-independent NLRs. 
 
NLRC2 deficiency in mice reduces LRV-mediated 
pathogenesis  
To determine whether LRV1-mediated upregulation of 
NLRC2 or NLRC5 in macrophages plays a pathogenic role in 
LgyLRV1+ infected mice, we investigated disease progres-
sion among mice deficient in NLRC2 or NLRC5 as compared 
to WT mice. Mice lacking NLRC2, showed significantly re-
duced parasite load and lesion swelling (Fig 7A and 7B). 
Oppositely, no discernible difference was seen between 
WT and NLRC5-/- mice (Fig 7C and 7D). These results indi-
cate that LRV1 promotes the virulence of its microbial host 
partially through NLRC2 in mice. 
 
DISCUSSION 
The innate immune response to Leishmania formed within 
the first hours after parasite inoculation is a determining 
factor for the outcome of leishmaniasis [1]. We previously 
revealed that the dsRNA genome of an endosymbiotic virus 
within virulent Leishmania species is able to act as a potent 
innate immunogen that worsens the outcome of cutane-
ous disease [5]. Although we showed the essential role of 
TLR3, we could not formally exclude the role of other PRRs 
in leishmaniasis such as the RIG-like receptors (RLRs) and 
various members of the NOD-like receptors (NLRs).  
In this study, we found that macrophage infection with 
LgyLRV1+ parasites resulted in the transcriptional up-
regulation of several inflammasome components such as 
caspase-1, IL-1β, NLRP3, and AIM2. These results mirrored 
those of a preliminary effort to profile the transcription of 
inflammasome components in a macrophage system of 
infection [25]. However, we found that L. guyanensis infec-
tion did not activate the inflammasome, irrespective of its 
LRV1 status. Notably, an infection in primed macrophages 
was unable to activate caspase-1 or IL-1β and mice defi-
cient in the key inflammasome components ASC and 
caspase-1/11 showed no change in their disease pheno-
type. Further, we found no role for RLR-signalling in re-
sponse to LRV1, as removing its key signalling adaptor pro-
tein MAVS had no effect on cytokine production or para-
site burden in vitro, nor did this defect have any impact on 
disease progression in vivo. As MAVS is also a central or 
synergising adaptor protein for other non-RLR pathways, 
the unchanged phenotype in MAVS-/- mice also excluded 
the RLR-independent pathway of virus-induced apoptosis 
via MAVS-MKK7-JNK2 [47]. The absence of a role for RLR 
signalling indicated that LRV1 was likely not able to exit the 
phagolysosome to engage these receptors in the cytoplasm 
and that LRV1 dsRNA recognition was limited to endosomal 
TLR3.  
NLRs are able to detect both PAMPs and DAMPs, which 
are present in the destructive inflammatory environment 
of a typical leishmaniasis lesion. NLRs have so far proven 
protective in murine leishmaniasis caused by L. amazonen-
sis, L. braziliensis and L. infantum. This protection was elic-
ited by an NLRP3-dependent production of nitric oxide 
(NO) involving IL-1β [24]. Upon incubation with LPS, the 
resultant active IL-1β induced by NLRP3 signalling carried 
out this response in an autocrine manner, whereby the IL-1 
receptor and its MyD88 adaptor protein were necessary 
and sufficient to trigger parasitotoxic oxidative stress via 
inducible nitric oxide synthase (iNOS). It should also be 
noted, however, that LPS can elicit a non-canonical activa-
tion of the inflammasome in the cytosol via caspase 11 and 
its CARD domain [48]. It is likely that production of IL-1β is 
not sufficient to control the disease for every Leishmania 
species,  since  L.  major  was   shown   to   induce   IL-1β   in 
FIGURE 5: L. guyanensis and L. infantum infection induce the up-regulation of the inflammasome inhibitory factor, A20. BMDMs from 
C57BL/6 WT mice were infected with LgyLRV1+, LgyLRV1-, Linf S1 or Linf S2 parasites or stimulated with poly(I:C) (p(I:C)) as a positive control 
for TLR3 activation. (A) At 4 or 8 hours after infection, cells were collected, proteins were extracted from cell lysates and were blotted for 
A20 and γ-tubulin. (B) Quantification of protein expression of LgyLRV1+ or LgyLRV1- infected or poly(I:C) treated macrophages. The graph is 
representative of four independent experiments, and shown as mean ± SD. Two-way ANOVA was used to calculate significance. *p < 0.05; 
**p < 0.01; ns: non-significant. 
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BMDMs when exposed to LPS, but lesion sizes were not 
increased in caspase-1 deficient mice [24]. Another group 
showed that blockade of IL-1β signalling rendered BALB/c 
mice resistant to the infection [27]. Oppositely, NLRP3 in-
flammasome activation was required to establish non-
healing infection with a particular strain of L. major [26]. 
Our data showed that, even in the presence of LPS, Lgy 
parasites did not activate the inflammasome. Therefore, 
the question of species-specific inflammasome activation 
and evasion remains to be determined. Of note, Leishma-
nia parasites can be abundantly coated with the leucine-
rich-repeat (LRR)-enriched surface antigen PSA-2. Interest-
ingly these antigens vary across Leishmania species, and 
have been associated to increased virulence [49], which 
could explain the discrepancies in inflammasome activa-
tion between different Leishmania species and/or strains. 
Aside from parasite species, we cannot yet exclude that 
other factors such as the site of infection (footpad or ear) 
and the dose of parasites injected, which differ remarkably 
between reports, could participate in inflammasome acti-
vation. 
Inflammasome evasion could be an essential virulence 
strategy in cutaneous leishmaniasis. This evasion could 
occur via the catalytic activity of GP63, a ubiquitous metal-
loprotease on the surface of the Leishmania parasite, 
which can cleave NLRP3 and inflammasome components 
as shown in vitro but no evidence on the impact of GP63 
has been provided to date in vivo [50]. Alternatively, the 
deubiquitinating enzyme A20, which is a negative regulator 
of NF-κB and TLR signalling in L. donovani infection [32] 
was attributed a new role in suppressing inflammasome 
activity [31, 33, 51]. We found that, similarly to L. donovani, 
L. guyanensis infection induced A20 expression in macro-
phages. Interestingly, at 4 hours post infection, A20 ex-
pression was higher in LgyLRV1+ infected macrophages, 
compared to LgyLRV1- or Poly (I:C) stimulation, suggesting 
an additive role for TLR3 stimulation. It will be interesting 
to assess whether the same inhibition of inflammasome 
activation by A20 is observed in models of Leishma-
nia/virus co-infection where exogenous viral infection ex-
acerbates the severity of L. guyanensis infection, promot-
ing parasite dissemination and disease relapses, reproduc-
ing the phenotype of LgyLRV1+ infection [52].  
The formation of an inflammasome is only one of the 
many possible signalling pathways of NLRs. Many NLRs 
respond to viral cues in inflammasome independent path-
ways. We found that LgyLRV1+ infection, or poly(I:C) treat-
ed macrophages, up-regulate the inflammasome inde-
pendent NLRs: NLRC2 and NLRC5. Moreover, we showed 
that the infection of mice deficient in NLRC2 but not NLRC5 
led to a reduction in parasite burden and lesion size. These 
results indicated that there could be an NLRC2–mediated 
host dependent virulence mechanism other than the LRV1-
mediated inflammatory response. NLRC2 drives the re-
cruitment of monocytes to the site of infection [42]. The 
LRV1-mediated hyperinflammatory response that pro-
motes parasite survival could require NLRC2-dependent 
monocyte infiltration, cells which could in turn serve as 
secondary host cells, thus explaining the reduction of dis-
ease severity in NLRC2-/- mice. This hypothesis will require 
further investigation. 
NLRC5 (CITA) is responsible for MHC-I transcription. 
The role of MHC-I on CD8 cells in leishmaniasis shows a 
distinct disease type-specificity as CD8+ T cells are detri-
mental to mucosal and metastatic infections [53], but pro-
tective in simple cutaneous leishmaniasis. The pathogenic 
role of CD8+ T cells in L. braziliensis infection was shown to 
be due to tissue-destructive levels of granzyme B [54]. It is 
thus interesting that NLRC5 deficiency in mice had no ef-
fect on disease phenotype in L. guyanensis infection irre-
spective of LRV1 content, indicating that CD8+ T cells pos-
sibly do not play an important role in LRV1-mediated pa-
thology.  
FIGURE 6: LRV1 induces the expression of inflammasome-independent NLRs: NLRC2 and NLRC5. (A-B) BMDMs from C57BL/6 mice were 
infected with LgyLRV1+ or LgyLRV1- parasites or stimulated with a synthetic TLR3 ligand, poly(I:C). After 6 hours, mRNA was quantified by 
qRT-PCR for NLRC1 and NLRC2 (A) or for NLRC5, NLRX1 and NLRC3 (B). The bar graphs are representative of at least 3 independent experi-
ments, using 2 technical and 2 biological replicates, and showed as mean ± SEM. Non-parametric Student’s t-test was performed. *p < 0.05, 
**p < 0.01, ***p < 0.001. A cut off value of 2-fold was shown as a dotted line. 
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Taken together, we were able to show that L. guyanen-
sis evades inflammasome activation, where no central 
components of the inflammasome impacted pathology in a 
murine model of disease, irrespective of the presence of 
LRV1. Additionally, we excluded the involvement of RLR 
receptors in the development of Lgy pathology, and con-
firmed that LRV1 does not stimulate this cytoplasmic dsR-
NA receptor. Considering the potently protective role of 
inflammasome activation previously found in infections by 
other Leishmania species, these results indicated that in-
flammasome evasion might be an important mechanism of 
virulence in Leishmania infection. Finally, as NLR and RLR 
pathways are the major non-TLR3 routes of dsRNA-induced 
inflammation, this work confirmed TLR3 as the major 
pathway of inflammatory pathology in LRV1-mediated cu-
taneous leishmaniasis. 
 
MATERIALS AND METHODS 
Ethical Statement 
All animal protocols in this publication were approved by the 
Swiss Federal Veterinary Office (SFVO), under the authoriza-
tion numbers VD2113.1 and VD2113.2. Animal handling and 
experimental procedures were undertaken with strict adher-
ence to ethical guidelines set out by the SFVO and under in-
spection by the Department of Security and Environment of 
the State of Vaud, Switzerland. 
 
FIGURE 7: NLRC2 reduces LRV-mediated pathogenesis. (A-D) Mice were infected with LgyLRV1+ or LgyLRV1- parasites in their hind foot-
pad. Weekly lesional swelling in infected NLRC2-/- (A) and NLRC5-/- (C) was monitored as a proxy for disease progression. At the peak of infec-
tion (4 weeks), parasite burden in infected NLRC2-/- (B) and NLRC5-/- (D) mice was measured by in vivo luminescence, by injecting mice intra-
peritoneally with 15mg/kg luciferin. The representative graph is shown from at least three independent experiments, using two biological 
replicates in duplicates, and showed as mean ± SEM. Significance was calculated by Student’s t-test (bar graphs) or one-way Anova (disease 
score), ns: non-significant. 
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In vitro parasite culture 
Two isogenic clones of L. guyanensis (MHOM/BR/75/M4147) 
showing uniformly high levels of LRV1 or completely lacking it 
were described previously [55]. We refer to these clones as 
LgyLRV1+ and LgyLRV1-, respectively. Both strains express a 
firefly luciferase gene (LUC), integrated stably into the locus of 
the small ribosomal subunit and displayed comparable lumi-
nescent efficacy [55]. In addition, two strains of L. infantum 
were used. The first one was isolated from a dog in Spain (JPC 
MCAN/ES/98/LLM-722) and will be referred as Linf S1, while 
the second one was isolated from a human patient in Switzer-
land (MHOM/CH/2016/BELA) and will be referred as Linf S2. 
Parasites were cultured in vitro as promastigotes at 26°C in 
freshly prepared Schneider’s insect medium (Sigma) supple-
mented with 10% heat-inactivated fetal bovine serum (PAA®), 
10mM HEPES and 50U/ml penicillin/streptomycin (Animed®), 
0.6mg/L biopterin and 5mg/L hemin (Sigma-Aldrich®). Each 
passage yielded infectious metacyclic promastigotes after 6 
days and stocks were kept no longer than 5 passages. 
 
Murine model of leishmaniasis 
All mice were bred in a specific pathogen-free housing facility 
at the University of Lausanne, Switzerland and backcrossed at 
least 10 times onto a C57BL/6 genetic background (purchased 
from Harlan Laboratories, Netherlands). Caspase-1/11
-/-
 and 
NLRC2
-/-
 were purchased from Jackson Laboratories 
(B6.129S2-Casp1tm1Flv/J and B6.129S1-Nod2tm1Flv/J respec-
tively). The following genetic knock-outs were a kind gift from 
Jürg Tschopp and previously described: MAVS
-/-
, ASC
-/-
, IL-1β
-/-
, 
and NLRC5-/- [36, 56-58]. Age-matched (6-8 weeks old) female 
mice were infected in the hind footpads with 3x10
6
 stationary 
phase LgyLRV1+ or LgyLRV1- promastigotes. Change in foot-
pad swelling was measured weekly using a Vernier caliper as a 
proxy for disease score. 
 
Parasite quantification by luminescence 
At the peak of infection (week 4/5) parasite burden was quan-
tified using in vivo imaging able to detect luminescence emit-
ted by luciferase-transfected parasites. Briefly, mice were 
injected intra-peritoneally with D-Luciferin sodium salt (Regis 
technologies®) prepared in PBS at a final concentration of 
15 mg/kg. After a 10min incubation, mice were anesthetized 
by continuous gas anesthesia and imaged using a Xenogen 
Lumina II imaging system (IVIS®, 10min exposure time). Total 
photon flux over the leishmanial lesions in the footpads was 
assessed using the associated software (Living Image®). 
 
BMDM culture, infection and stimulation 
Bone marrow cells were extracted from naive C57BL/6 mice. 
Erythrocytes were removed by lysis using ACK lysis buffer 
(1,5M NH4Cl, 100mM KHCO3, 10mM EDTA-2Na) and then in-
cubated with macrophage differentiation medium (complete 
DMEM supplemented with L929-conditioned media) at 37°C. 
After 6 days of differentiation, adherent BMDMs were isolated 
and plated at 1x10
6
/ml in 48 well plates before being stimu-
lated. Inflammasome activity assays used a pre-stimulation 
step with 200 ng/ml LPS (Sigma-Aldrich®) for 3 hours. Cells 
were then washed and infected (1:10) with stationary phase 
LgyLRV1+ or LgyLRV1- parasites or stimulated with the syn-
thetic TLR3 ligand, poly(I:C) (2 µg/ml, Sigma-Aldrich®) for 24 
hours at 37°C. A positive control was treated with 5 µM nigeri-
cin (Sigma-Aldrich®) for 1 hour, while a negative control was 
left unstimulated after LPS pre-treatment. Alternatively, for 
A20 measurement, BMDMs were infected (1:10) with station-
ary phase LgyLRV1+, LgyLRV1-, Linf S1 or Linf S2 parasites or 
stimulated with poly(I:C) for 4 or 8 hours at 37°C. 
 
Western blot 
BMDMs were lysed with a mixture of RIPA Buffer IV (Biotech 
RB4448), and a Protease/Phosphatase inhibitor cocktail (Cell 
Signaling 5872S) in PBS. Laemmli’s Sample Buffer was added 
before lysates were size-fractionated by SDS-PAGE and wet-
transferred to a nitrocellulose membrane. Western Blotting 
was performed using the following antibodies: rabbit polyclo-
nal anti-mouse caspase-1 p10 (Santa Cruz, SC514), goat poly-
clonal anti-mouse IL-1β (R&D Systems, AF-401-NA), rabbit 
anti-mouse A20 (Cell Signaling, D13H3), mouse monoclonal 
anti-mouse γ-tubulin (Sigma-Aldrich® T6557), goat anti-rabbit 
IgG HRP conjugated (Promega W4011) and goat anti-mouse 
IgG HRP conjugated (Promega W4021). Where indicated, pro-
tein expression was quantified with densitometric analysis 
using ImageJ software. 
 
High Content Microscopy 
BMDMs were counted with Vi-Cell® (Beckman Coulter). Then, 
0.1x10
6
 BMMs were seeded on Falcon® 96 Well clear-bottom 
Tissue-Culture treated plate. Cells were infected with station-
ary phase LgyLRV1+ or LgyLRV1- parasites (1:10) for 24 hours 
and then fixed with freshly made 3.7% PFA in PBS. Cells were 
subsequently stained with DAPI to visualize the nuclei of para-
sites and macrophages and washed in PBS using a Biotek Mul-
tioFlo FX plate washer. 49 (7x7 square) images from each well 
with x40 lens were acquired using ImageXpress Micro XLS and 
analyzed using MetaExpress software. 
 
Statistical analysis 
Statistical significance was determined using an unpaired par-
ametric t-test (for single-point analysis on bar-graphs) or a 
one-way Anova (x/y disease curves) as calculated by 
GraphPad® software (Prism™ v5a). Significance was recog-
nized when p ≤ 0.05 and represented in three ranks namely *: 
p ≤ 0.05, **: p ≤ 0.01 and ***: p ≤ 0.001. 
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